Posts Tagged ‘ADT’

Can Therapy for Prostate Cancer Increase Risk of Alzheimers

Wednesday, December 9th, 2015

Logos 005A new study published in the Journal of Clinical Oncology concluded  that men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer’s later in life than those who did not use the therapy based on the analysis of medical records. In addition, men with the longest duration of using ADT were even more likely to suffer Alzheimer’s. Researchers said this does not prove that ADT increases the risk of Alzheimer’s but point to that possibility and are consistent to other evidence that low levels of testosterone may weaken the brain of aging individuals resistance to Alzheimer’s.  The researchers said “We wanted to contribute to the discussion regarding the relative risk and benefits of ADT. and no one had yet looked at the association between ADT and alzheimer’s disease.” “Based on the results of our study, an increase risk of Alzheimer’s disease is a potential adverse effect of ADT, but further research is needed befre considering changes to clinical practice.”

For this study, the researchers evaluated large sets of medical records from two hospitals on the east and west coasts.  In total, there were about 5 million patients. of whom 16,888 had a diagnoses of prostate cancer and met the other criteria of the study. Of the 16,888 prostate cancer patients about 2,400 had received ADT and had the necessary follow up records. This group was compared with a control group of prostate cancer patients who did not receive ADT that were matched by age and other factors.

Using two different statistical analysis methods, the researchers  showed that the ADT group , xompared to the control group, had significantly more Alzheimer’s diagnoses in later years and showed that the ADT group were about 88 percent more likely to develop Alzheimer’s during the follow up period. Further studies are planned  to determine whether ADT does increase Alzheimer’s risk using data from large cancer registries.

A common Prostate Cancer Treatment Reduces Survival in Older Men.

Wednesday, December 10th, 2014


A new study published in European Urology concluded that a common prostate cancer therapy known as ADT should not be used in men whose cancer has not spread beyond the prostate  Researchers found that the therapy exposed them to more adverse side effects and was associat3d with increased risk of death and deprived the men of the opportunity for a cure by other methods.

ADT or androgen deprivation therapy involves injecting or implanting medication that disrupts the bodies ability to make testosterone and has significant side effects such as heart disease, diabetes, increased weight gain and impotence and potential earlier death.

According to the authors  the treatment has become a mainstay for prostate cancer that has metastasized or spread beyond the prostate gland. and others used it with radiation therapy. However, the authors say there is no evidence for use of ADT for low risk or localized prostate cancer despite its use in these patients. This misuse of ADT therapy lead to changes in Medicare reimbursement policires for ADT in 2004 with a resulting 40 per cent drop in reimkbursement and a reduction in inappraopriate uise of ADT from 38.7 percent to 25.7 percentfor newly diagnosed localized prostate cancers. The current study  study ” hypothesuized that adverse effects of ADT might be more pronounced in men with longer life expectencies since they would likely be treated with ADT for a longer period and be exposed to more treatment-related side effects. ” Of a  population of 46,376 men diagnosed with localized prostate cancer who did not undergo radical prostectomy or radiation therapy for prostate cancer diagnosed between 1992 and 2009 thirty eight and a half percent were treated with ADT and the hypothesis was confirmed. Findings showed that primary ADT was associated with decreased survival in men with localized prostate cancer relative to men who received noa ctive treatment. Thus, ADT should not be used as a primary treatment for men with prosatate cancer that has not spread beyond the prostate or men with moderate or high disease undergoing radiation therapy.

Bone Decay Linked to A Common Prostate Cancer Treatment

Friday, October 22nd, 2010


Research to be published in the Journal of Clinical Endocrinology and Metabolism and reported on Science Digest concluded that androgen deprivation therapy (ADT), a common prostate cancer therapy, is associated with decay of the hard outer shell and the spongy inner mesh of bones. Because prostate cancer relies on male hormones for its growth, ADT that suppresses or blocks the production or action of these commonly used.

Researchers followed 26 men with prostate cancer who were on ADT in a 12 months prospective observational study. At different times during the study period sex steroid levels, bone turnover markers, and bone mineral densities were taken. In addition, three dimensional high resolution peripheral quantitative computed tomography (HR-pQCT) was used to assess bone structure changes. Results showed the decay mentioned earlier.